Geisbüsch C, Lichy C, Richter D, Herweh C, Hacke W, Nagel S
Neurologische Klinik, Universität Heidelberg, INF 400, 69120, Heidelberg, Deutschland.
Nervenarzt. 2014 Feb;85(2):211-20. doi: 10.1007/s00115-013-4000-8.
Thrombosis of cerebral veins or sinuses (CVST) is a rare condition. In a monocentric retrospective cohort study the clinical characteristics, risk factors, radiological findings as well as course and prognosis of patients over the past 15 years were examined.
Between January 1998 and March 2013 all patients who were treated as inpatients for CVST at the department of neurology of the University of Heidelberg were systematically registered in a database. Along with all relevant clinical data the modified Rankin scale (MRS) was used to measure the clinical severity. A follow-up visit was performed at three time points. The odds ratios (OR) were calculated to establish predictors of good outcome (MRS 0-2), mortality at discharge and at follow-up. Significant variables after univariate analysis were tested for independency in a multivariate logistic regression model.
A total of 143 patients were included in the study. The median age was 43 years (range 17-74 years) and 67.4 % of patients were female. The most common symptoms were headache (70.6 %), seizures (50.4 %) and paresis (37.8 %). The most prominent clinical risk factor was oral contraception (40.4 %). The two most common localizations of thrombosis were the transversal sinus with the sigmoid sinus (66.4 %) and the sagittal superior sinus (47.6 %). On admission 42.7 % of patients suffered additionally from intracerebral hemorrhage and 12.6 % from congestive infarction. Of the patients 9.5 % (10 out of 105) showed a pathologically reduced activated protein C (APC) resistance and 8.4 % (6 out of 94) a prothrombin mutation. All patients were initially treated with heparin and 88.7 % were switched to cumarin during the course of the disease. The median duration of anticoagulation was 15.75 months (range 1-121 months). On discharge 77.7 % had a good outcome and the in-hospital mortality was 4.7 %. The median time to follow-up in 108 patients was 36 months (range 3-132 months), 74.1 % of patients had a good outcome (MRS 0-2) and 18.5 % died. Independent predictors of in-hospital mortality were MRS on admission (OR 2.2, 95 % CI 1.03-4.7) and of mortality at follow-up the presence of a malignant disease (OR 50.2, 6-423) and intracerebral hemorrhage on admission (OR 10.3, 1.7-62.6).
The results of this study are in line with previously published data on CVST. The most prominent clinical risk factors for CVST were female gender and oral contraception. At discharge from hospital and 3 years after CVST approximately 75 % of patients achieved a good clinical outcome. A severe clinical syndrome and the presence of an intracerebral hemorrhage on admission were independent predictors of mortality.
脑静脉或静脉窦血栓形成(CVST)是一种罕见疾病。在一项单中心回顾性队列研究中,对过去15年患者的临床特征、危险因素、影像学表现以及病程和预后进行了研究。
1998年1月至2013年3月期间,海德堡大学神经病学系所有因CVST住院治疗的患者均被系统登记在一个数据库中。除所有相关临床数据外,改良Rankin量表(MRS)用于衡量临床严重程度。在三个时间点进行随访。计算比值比(OR)以确定良好预后(MRS 0 - 2)、出院时及随访时死亡率的预测因素。单因素分析后的显著变量在多因素逻辑回归模型中进行独立性检验。
本研究共纳入143例患者。中位年龄为43岁(范围17 - 74岁),67.4%的患者为女性。最常见的症状是头痛(70.6%)、癫痫发作(50.4%)和轻瘫(37.8%)。最突出的临床危险因素是口服避孕药(40.4%)。血栓形成最常见的两个部位是横窦与乙状窦(66.4%)和上矢状窦(47.6%)。入院时,42.7%的患者还患有脑出血,12.6%患有充血性梗死。9.5%的患者(105例中的10例)活化蛋白C(APC)抵抗病理性降低,8.4%(94例中的6例)凝血酶原突变。所有患者最初均接受肝素治疗,88.7%在病程中改用香豆素。抗凝的中位持续时间为15.75个月(范围1 - 121个月)。出院时77.7%的患者预后良好,住院死亡率为4.